

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/824,364	04/02/2001	Ismat Ullah	HX96 (DIV)	7174
7	7590 06/06/2003			
Marla J. Mathias			EXAMINER	
Patent Departm			WEBMAN, I	EDWARD J
P.O. Box 4000 Princeton, NJ 08543-4000			ART UNIT	PAPER NUMBER
		,	1617	a
			DATE MAILED: 06/06/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No. Applicant(s)
Office Action Summary	Examiner Group Art Unit
	WEBMIN 1617
-The MAILING DATE of this communication appear	s on the cover sheet beneath the correspondence address—
Period for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO OF THIS COMMUNICATION.	EXPIRE MONTH(S) FROM THE MAILING DATE
from the mailing date of this communication.	
Status	
Responsive to communication(s) filed on $\frac{4}{2}$	<i>t</i> / 03
☐ This action is FINAL.	
<ul> <li>Since this application is in condition for allowance except faccordance with the practice under Ex parte Quayle, 1935</li> </ul>	or formal matters, <b>prosecution as to the merits is closed</b> in C.D. 1 1; 453 O.G. 213.
Disp sition of Claims	
Claim(s) 28-47	is/are pending in the application.
Of the above claim(s) 29-35	is/are pending in the application. is/are withdrawn from consideration.
□ Claim(s) 2 f, 3 6 - 4 7	is/are rejected.
☐ Claim(s)	
□ Claim(s)	·
Application Papers	requirement.
☐ See the attached Notice of Draftsperson's Patent Drawing	Review PTO-948
☐ The proposed drawing correction, filed on	• •
☐ The drawing(s) filed on is/are objected	
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119 (a)-(d)	
<ul> <li>□ Acknowledgment is made of a claim for foreign priority und</li> <li>□ All □ Some* □ None of the CERTIFIED copies of the received.</li> <li>□ received in Application No. (Series Code/Serial Number received in this national stage application from the Interest.)</li> </ul>	ne priority documents have been
*Certified copies not received:	·
Attachment(s)	
Information Disclosure Statement(s), PTO-1449, Paper No	(s) Interview Summary, PTO-413
□ Notice of Reference(s) Cited, PTO-892	□ Notice of Informal Patent Application, PTO-152
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	• •
·	Acti n Summary

U. S. Patent and Trademark Office PTO-326 (Rev. 9-97)

Part of Paper No. \_\_\_\_9\_\_\_

Application/Control Number: 09/824,364

Art Unit: 1617

Applicant's election of Group II and a method of using granules in Paper No. 5 and 8 respectively are acknowledged. Because applicant did not distinctly and specifically point out the any errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 28, 41, 44-47 are rejected under 35 U.S.C. 102(b) as being anticipated by Eisman et al.

Eisman et al teach a method of lowering cholesterol by administration is a combination of an HMG CoA reductase inhibitor and a pharmaceutical which reduces cholesterol other than by inhibiting HMG CoA reductase (abstract), Lovastatin (column 8 lines 56-59) and aspirin (column 13 line 42) are disclosed. Tablets and capsules are disclosed (column 15 line 10). Antioxidants such as ascorbic acid are disclosed (column 15 line 14).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 28, 36-47 are rejected under 35 U.S.C. 103(a) as being unpatentable over Eisman et al in view of Eichel et al and Hodges et al.

Art Unit: 1617

Eisman is discussed above.

Eichel et al., teach sustained release preparations of aspirin wherein the aspirin is uncoated as well as coated with an enteric coast (abstract). Granular drugs are specified (column 5 line 65).

Hodges et al., teach enteric-coated pellets (abstract). Pravastatin is specified (table, column 5).

It would have been obvious to one of ordinary skill to deliver the composition of Eisman et al with the vehicle of Eichel et al., to achieve the beneficial effect of controlled release. As to coating statins as well, Hodges et al., teach such.

Claims 28, 36-47 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicants provide no evidence of "Preventing" in claim 46.

No claims allowed.

Item on the PTO form 1449 supplied with paper #4 has been lined through because only the odd numbered pages were supplied.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Edward Webman whose telephone number is (703) 308-4432. The examiner can normally be reached on Monday to Friday 9 Am 5 PM.

Application/Control Number: 09/824,364

Art Unit: 1617

Page 4

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, S. Padmanabhan can be reached on (703) 305-1877. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3592 for regular communications and (703) 305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Webman/LR May 22, 2003

